Eli Lilly and Company (LLY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Core Insights - Eli Lilly is actively engaging with the administration regarding policy-related uncertainties in the pharmaceutical sector, particularly following the first Most Favored Nation (MFN) executive order [3][4] - The company has reported positive conversations with the administration, focusing on reducing patient out-of-pocket costs in the U.S., citing past successes such as capping insulin prices at $35 [4] Company Engagement - Lucas E. Montarce, CFO of Eli Lilly, participated in the Goldman Sachs 46th Annual Global Healthcare Conference, indicating the company's commitment to addressing industry challenges [1][2] - The company is prepared to discuss its strategies and experiences in managing pricing and patient access during industry conferences [3][4]